Decision Resources Research Reports

Title	Published	Price
Chronic Obstructive Pulmonary Disease By: Decision Resources A novel, nonsteroidal, anti-inflammatory therapy that increases the forced expiratory volume in one second (FEV1) over placebo equal to or greater than fluticasone (GlaxoSmithKline’s Flovent) for the treatment of COPD. Using Target Product \| more...	3/30/2008	$5,625.00
Pancreatic Cancer (Advanced) By: Decision Resources An emerging therapy that improves median overall survival better than the gemcitabine plus erlotinib regimen for the treatment of advanced pancreatic cancer. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Ovarian Cancer (Advanced Stage) By: Decision Resources An agent or regimen that offers increased median overall survival compared with paclitaxel/carboplatin for the treatment of advanced ovarian cancer. Using Target Product Profiles in Your Market Strategy Our Target \| more...	3/30/2008	$5,625.00
Non-Small-Cell Lung Cancer (Locally Advanced) By: Decision Resources "An adjunct to chemoradiotherapy that improves overall survival better than adjunct paclitaxel/carboplatin for the treatment of unresectable LA-NSCLC" Using Target Product Profiles in Your Market Strategy Our Target Product Profiles \| more...	3/30/2008	$5,625.00
Non-Small-Cell Lung Cancer (Advanced) By: Decision Resources A therapy that improves median overall survival (MOS) compared with bevacizumab (plus paclitaxel/carboplatin) for the treatment of advanced non-small-cell lung cancer. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Multiple Myeloma (Symptomatic) By: Decision Resources An emerging therapy used in combination with bortezomib that improves median overall survival compared with bortezomib alone for the treatment of relapsed multiple myeloma (rMM). Using Target Product Profiles in Your Market \| more...	3/30/2008	$5,625.00
Colorectal Cancer (Stage IV) By: Decision Resources A therapy that improves median overall survival better than the IFL plus bevacizumab regimen for the first-line treatment of stage IV colorectal cancer. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Colon Cancer (Stage III) By: Decision Resources A therapy that improves disease-free survival over FOLFOX4 at three years for the treatment of stage III colon cancer. Using Target Product Profiles in Your Market Strategy Our Target \| more...	3/30/2008	$5,625.00
Chemotherapy-Induced Nausea and Vomiting By: Decision Resources An adjunctive therapy that elicits an improved complete response rate for delayed CINV compared with adjunctive aprepitant in patients taking highly emetogenic chemotherapy. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$5,625.00
Type 2 Diabetes By: Decision Resources A weight-neutral oral antidiabetic drug for the treatment of type 2 diabetes. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market potential of \| more...	3/30/2008	$5,625.00
Fibromyalgia By: Decision Resources A drug with effi cacy on multiple measures (including pain, global outcome, fatigue, sleep, and mood) equal to that of pregabalin at 8-14 weeks but that sustains its effect on pain at 6 months. \| more...	3/30/2008	$5,625.00
Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008 By: Decision Resources Over the past two decades, the German pharmaceutical market has undergone a greater number of radical reforms than any other major drug market. With the German government exerting pressure on all sectors of the pharmaceutical \| more...	3/26/2008	$2,250.00
Key Trends in the Political and Reimbursement Environment for Cancer Drugs By: Decision Resources Cancer therapies make up one of the fastest-growing therapeutic areas in the global pharmaceutical market. IMS Health expects global sales of cancer therapies to more than double in just four years, exceeding $65 billion in \| more...	3/26/2008	$1,125.00
How to Get Ahead with Pharmacogenomics By: Decision Resources Pharmacogenomics (PGx) is an evolutionary—not a revolutionary—process. The “blockbuster” business model is, of course, still relevant to the pharmaceutical industry, but at the same time, companies must adopt technologies that will enable them to develop \| more...	3/19/2008	$1,125.00
Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies? By: Decision Resources Monoclonal antibodies (MAbs) are very hot commodities in today’s pharmaceutical marketplace, and in recent years, the growth in the number of MAbs under development has far outpaced the growth of other types of drugs. With \| more...	3/18/2008	$1,125.00
Can a New Antidepressant Establish Itself in a Highly Competitive Market? By: Decision Resources With the antidepressant market approaching its saturation point, emerging agents face increasing difficulty capturing market share from the multitude of already available branded and generic drugs. Companies hoping to launch new products into this market \| more...	3/18/2008	$1,125.00
Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents? By: Decision Resources Research data on COPD increasingly point to systemic infl ammation as the cause of many of the severe comorbidities associated with the disease. However, agents under study for COPD continue to focus only on the \| more...	3/18/2008	$1,125.00
What Strategies Will Yield Novel Treatments for Autoimmune Disease? By: Decision Resources More than 80 autoimmune disorders have been identified, all involving aberrant immune responses to self-antigens. The emergence of biologic agents, such as the interferons and the TNF-á inhibitors, has greatly improved the treatment outlook for \| more...	3/14/2008	$1,125.00
Navigating the Drug Discovery Landscape: A Strategic Overview of Pharmaceutical R&D By: Decision Resources Pharmaceutical companies must find successful strategies for future drug discovery. Increased market pressures, looming drug patent expirations, and dramatically increasing drug development costs have caused pharmaceutical companies to search for new ways to increase R&D \| more...	3/14/2008	$1,125.00
Chronic Organ Transplant Rejection: Opportunities Await Improved Therapies By: Decision Resources Introduction The organ transplant market, though growing only slowly in recent years, offers substantial opportunities for drug developers. This market encompasses therapies that must be taken lifelong, ensuring a steady stream of revenue throughout a \| more...	3/10/2008	$1,125.00
Dealmaking and Financing: Buying in Innovation By: Decision Resources Introduction: Pharmaceutical companies are on the hunt for new product and technology opportunities to augment their product development pipelines. Pharmaceutical giants and big biotech alike are exploring new avenues of cooperation to gain early access \| more...	3/6/2008	$1,125.00
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers By: Decision Resources Validating a biomarker is a resource-intensive undertaking. Is it worth it? We say, Yes. A biomarker that wins “known validated” status is best positioned for rewards: regulatory approval, optimal reimbursement, incorporation into personalized medicine approaches \| more...	2/29/2008	$1,669.00
Diagnostic Imaging Market: Recent Advances and Future Trends By: Decision Resources Introduction Scientific and technological developments are making the field of diagnostic imaging a growth industry. In 2007, the U.S. market for diagnostic imaging technologies was valued at more than $7 billion, and it is expected \| more...	2/21/2008	$1,669.00
Pharmaceutical Pricing and Reimbursement in the United States, 2008 By: Decision Resources Introduction The United States dominates the world’s pharmaceutical markets, not least because it offers pharmaceutical companies a speedy, effi cient drug registration process and unrivaled freedom to negotiate drug prices and reimbursement—but a rising chorus \| more...	2/19/2008	$2,250.00
Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors By: Decision Resources Introduction Despite the variety of efficacious oral antidiabetics available to treat type 2 diabetes—many of them available generically—the unmet need in this disease remains high. In October 2006, the launch of Merck’s Januvia (sitagliptin) introduced \| more...	2/14/2008	$1,125.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/23/2009 - 2